FORM 5

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

-	_		
	Washington,	D.C.	20549

ANNUAL ST	TATEMENT (OF CHANGES	IN BENEFICIAL

OMB APPROVAL								
OMB Number:	3235-0362							
Estimated average burden								
hours per response:	1.0							

By Trust(3)

to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 3 Holdings Reported.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OWNERSHIP

Form 4 Transact	tions Reported.		or Section 30(h	h) of the Inves	tment Company	Act of 19	140			
1. Name and Addre Nandabalan l		2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI]					ationship of Reporting Person(s) to k all applicable) Director 10% (
(Last) C/O BIOXCEL	(First) THERAPEUTIC	(Middle)	3. Statement for 12/31/2020	or Issuer's Fisc	cal Year Ended (I	ay/Year)	Officer (give ti below)	Officer (give title below) b		
555 LONG WH	4. If Amendme	nt, Date of Or	iginal Filed (Mont		6. Individual or Joint/Group Filing (Check Applicable					
(Street) NEW HAVEN	CT	06511	_					X Form filed by	One Reporting More than One	
(City)	(State)	(Zip)								
	Tal	ble I - Non-Deriv	ative Securiti	ies Acquir	ed, Dispose	d of, o	r Benefici	ally Owned		
Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Acquired (A) or Dispo Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct	7. Nature of Indirect Beneficial
			(Month/Day/Year)	8)	Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	(D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock		07/24/2020		G	80,000	D	\$0	\$0 0		
Common Stock		12/01/2020		G	185,150	D	\$0	9,020,000(1)	I	See Footnote ⁽¹⁾
Common Stock		12/01/2020		G	185,150	D	\$0	9,020,000(2)	I	See Footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

Common Stock

- 1. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for
- 2. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
- 3. Shares held by The Sunanda Family Trust.

/s/ Richard Steinhart, as Attorney in Fact for Krishnan 02/16/2021 Nandabalan

1,000

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.